Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma

Diagnostic Pathology

Hoda H Abou Gabal¹  Naglaa S Ahmed¹  Ola H Nada¹ 

[1] Department of pathology, faculty of Medicine, Ain Shams university, Cairo, Egypt

关键词: Immunohistochemistry;    Prognostic factors;    Human leukocyte antigen;    Osteosarcoma;   

Others  :  802055
DOI  :  10.1186/1746-1596-9-72

 received in 2013-10-08, accepted in 2014-03-18,  发布年份 2014

【 摘 要 】

Background

Defects in Human Leukocyte Antigen (HLA) class I antigen expression and/or function in tumor cells have been extensively investigated, because of their potential role in the escape of tumor cells from T cell recognition and destruction. The researchers evaluated HLA class I expression in tumor tissue as a prognostic factor in osteosarcoma patients and as a predictor of their survival. This retrospective cohort study was conducted at the pathology laboratory of Ain Shams University Hospital, and Ain Shams University Specialized Hospital during the period between January 2009 and January 2012.

Methods

The researchers investigated HLA class I expression in primary osteosarcoma by immunohistochemistry using EMR8-5 mAbs. Furthermore, researchers evaluated the correlation between HLA class I expression and the clinicopathological status and outcome in formalin fixed paraffin embedded tissues from thirty six (36) patients with osteosarcoma.

Results

A high expression of HLA class I was detected in 18 (50) % of tumor samples examined; while tumors with low or negative expression represented 9 (25%) cases each. Data indicate that the overall survival rate of patients with tumors highly expressing HLA class I was significantly higher than those with low or negative expression.

Conclusion

Down-regulation of class I antigen expression is associated with features of aggressive disease and a poorer prognosis. Therefore, it is imperative to identify HLA as a prognostic factor at the time of diagnosis to detect chemotherapy-resistant tumors and to generate a modified treatment regimen.

Virtual slides

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1159334857109547 webcite.

【 授权许可】

   
2014 Nada et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for Pediatric osteosarcoma. Oncologist 2004, 9(4):422-441.
• [2]Fagioli F, Biasin E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M, Madon E: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant 2008, 41(Suppl 2):S131-S134.
• [3]Haydon RC, Luu HH, He TC: Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007, 454:237-246.
• [4]Kansara M, Thomas DM: Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007, 26(1):1-18.
• [5]Ritter J, Bielack SS: Osteosarcoma. Ann Oncol 2010, 21(7):vii: 320-vii: 325.
• [6]Sakamoto A, Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008, 3(3):228-231.
• [7]Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F: Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007, 7(2):169-181.
• [8]Klein MJ, Siegal GP: Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 2006, 125:555-581.
• [9]Fletcher C, Unni K, Mertens F: Conventional Osteosarcoma. In Pathology and Genetics of Tumors of Soft Tissue and Bone. 4th edition. Lyon, France: IARC Press; 2013.
• [10]Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6(7):1075-1085.
• [11]Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles AS, Hartmann O: Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome–the French pediatric experience. Cancer 2005, 104(5):1100-1109.
• [12]Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006, 32(6):423-436.
• [13]Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007, 2:6. BioMed Central Full Text
• [14]Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D: Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997, 350(9082):911-917.
• [15]Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P: Children’s Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol 2007, 25(15):2057-2062.
• [16]Tan ML, Choong PF, Dass CR: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther 2009, 8(2):106-117.
• [17]Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005, 23(3):559-568.
• [18]Carsi B, Rock MG: Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 2002, 397:53-61.
• [19]Heck RK Jr, Stacy GS, Flaherty MJ, Montag AG, Peabody TD, Simon MA: A comparison study of staging systems for bone sarcomas. Clin Orthop Relat Res 2003, 415:64-71.
• [20]Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006, 106(5):1154-1161.
• [21]Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20(3):776-790.
• [22]Grimer RJ, Taminiau AM, Cannon SR: Surgical Subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg (Br) 2002, 84(3):395-400.
• [23]Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M: Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep 2002, 9(1):171-175.
• [24]Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol 2009, 20(5):955-960.
• [25]Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z: The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2010, 31(4):552-558.
• [26]Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M: HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007, 98(9):1424-1430.
• [27]Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, Masumori N, Sato N, Tsukamoto T: Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci 2009, 100(12):2331-2334.
• [28]Bubeník J: MHC class I down-regulation: tumor escape from immune surveillance? (Review). Int J Oncol 2004, 25(2):487-491.
• [29]Hosch SB, Izbicki JR, Pichlmeier U, Stoecklein N, Niendorf A, Knoefel WT, Broelsch CE, Pantel K: Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 1997, 74:582-587.
• [30]Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999, 154(3):745-754.
• [31]Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S: HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005, 11(1):67-72.
• [32]Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006, 118(1):6-10.
• [33]Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T: Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 2007, 177(4):1269-1272.
• [34]Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H: Downregulation of HLA Class I molecules in the tumor is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 2008, 99(9):1462-1467.
• [35]Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H, Natsugoe S: Clinical implication of HLA class I expression in breast cancer. BMC Cancer 2011, 11:454. BioMed Central Full Text
• [36]Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E: Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005, 65(9):3937-3941.
• [37]Kamarashev J, Ferrone S, Seifert B, Böni R, Nestle FO, Burg G, Dummer R: TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001, 95(1):23-28.
• [38]Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005, 117(2):248-255.
• [39]Seliger B: Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008, 57(11):1719-1726.
• [40]Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997, 18:89-95.
• [41]Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T, Sato N: Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 2012, 62(5):303-308.
• [42]Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K, Ichimiya S, Tamura Y, Torigoe T: Molecular pathological approaches to human tumor immunology. Pathol Int 2009, 59(4):205-217.
• [43]Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T: HLA-class I expression in gastric cancer. J Surg Oncol 2008, 97(7):605-608.
• [44]Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N: Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006, 97(12):1374-1380.
• [45]Zhu H, Tang J, Tang M, Cai H: Up regulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis. Diagn Pathol 2013, 8(1):183. BioMed Central Full Text
• [46]Liang X, Wang D, Wang Y, Zhou Z, Zhang J, Li J: Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol 2012, 7:84. BioMed Central Full Text
• [47]Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984, 2(6):617-624.